Terravitals

Terravitals is a New York-based biotechnology company focused on unlocking the therapeutic potential of the soil microbiome through advanced metagenomics. Founded as a spin-out from Dr. Sean Brady’s laboratory at The Rockefeller University, the company employs a culture-independent platform to sequence and analyze environmental DNA for novel biosynthetic gene clusters. This approach allows Terravitals to discover bioactive small molecules that were previously inaccessible via traditional laboratory cultivation. The company's primary research efforts are directed toward developing next-generation anti-infectives and oncology therapeutics. By bridging the gap between environmental genetic diversity and drug development, Terravitals aims to address the growing challenge of antimicrobial resistance and other unmet medical needs.